Compare Stanley Black & Decker, Inc. (SWK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Stanley Black & Decker, Inc. trades at $104 (market cap $15.50B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.6× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.27% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SWK | VRTX | |
|---|---|---|
Market Cap | $15.50B | $132.79B |
52-Week High | $104.00 | $529.65 |
52-Week Low | $62.12 | $376.62 |
Enterprise Value | $19.67B | $126.92B |
Dividend Yield | 3.27% | — |
Sector | — | Health |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $103.89, up 2.82% today, showing strong momentum after recent earnings beats. The stock demonstrates improving fundamentals with Q2 2026 EPS of $1.57 beating estimates by 30%, while technical indicators show bullish moving averages but overbought RSI levels. Recent corporate developments include debt reduction of $1.7 billion and a dividend increase to $0.84 per share.
SWK presents a mixed outlook with strong operational improvements and margin expansion offset by valuation concerns. The stock trades above analyst consensus target of $93.67, suggesting limited near-term upside. Key opportunities include continued margin recovery and market share gains, while risks involve economic sensitivity and competitive pressures in the tools industry.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
